Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.13 which represents a decrease of $-1.26 or -1.35% from the prior close of $93.39. The stock opened at $93.5 and touched a low ...